Shots:
- OliX & Eli Lilly have entered into a global license agreement to develop & commercialize OliX’s OLX75016 for metabolic-associated steatohepatitis (MASH) as well as other cardiometabolic indications
- As per the agreement, Eli Lilly will make an initial payment of ~$630M to OliX for completing the ongoing P-I trial of OLX75016 in Australia, after which Lilly will handle further development
- In preclinical models, OLX75016 (RNAi therapeutic) has shown efficacy againstefficacy against MASH with liver fibrosis & other cardiometabolic diseases
Ref: Businesswire | Image: OliX & Eli Lilly
Related News:- Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
